MBRX vs. MIRA, AKTX, ABVC, ELAB, ERNA, MTEM, IMNN, GHSI, PPBT, and CMMB
Should you be buying Moleculin Biotech stock or one of its competitors? The main competitors of Moleculin Biotech include MIRA Pharmaceuticals (MIRA), Akari Therapeutics (AKTX), ABVC BioPharma (ABVC), Elevai Labs (ELAB), Eterna Therapeutics (ERNA), Molecular Templates (MTEM), Imunon (IMNN), Guardion Health Sciences (GHSI), Purple Biotech (PPBT), and Chemomab Therapeutics (CMMB). These companies are all part of the "pharmaceutical preparations" industry.
MIRA Pharmaceuticals (NASDAQ:MIRA) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, community ranking, media sentiment, risk and dividends.
Moleculin Biotech received 227 more outperform votes than MIRA Pharmaceuticals when rated by MarketBeat users.
35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are owned by institutional investors. 6.7% of Moleculin Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
MIRA Pharmaceuticals' return on equity of -87.19% beat Moleculin Biotech's return on equity.
In the previous week, Moleculin Biotech had 10 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 14 mentions for Moleculin Biotech and 4 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 0.83 beat Moleculin Biotech's score of -0.45 indicating that Moleculin Biotech is being referred to more favorably in the news media.
Moleculin Biotech has a consensus target price of $35.00, suggesting a potential upside of 609.94%. Given MIRA Pharmaceuticals' higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than MIRA Pharmaceuticals.
Summary
Moleculin Biotech beats MIRA Pharmaceuticals on 8 of the 10 factors compared between the two stocks.
Get Moleculin Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Moleculin Biotech Competitors List
Related Companies and Tools
